Home › Funds › Nitorum Capital, L.P. › UTHR
Nitorum Capital, L.P. position in UTHR
UNITED THERAPEUTICS CORP DEL · Health Care
Nitorum Capital, L.P. reported holding 10,664 shares of UTHR (UNITED THERAPEUTICS CORP DEL) in its Q2 2026 13F filing — a position valued at US$5.8M, representing 3.94% of its reported portfolio and ranking #12 among its reported holdings. Nitorum Capital, L.P. has disclosed UTHR holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Nitorum Capital, L.P.'s UTHR position evolved
Nitorum Capital, L.P. first disclosed a stake in UTHR in Q3 2023 at 111,700 shares (US$25.2M). The position peaked in Q2 2024 at 140,822 shares, worth US$44.9M. Across 12 filings, Nitorum Capital, L.P. increased the stake 2 time(s), trimmed it 9 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 10,664 shares valued at US$5.8M — a reduction of -800 shares quarter over quarter.. Notable position changes include a 36% trim in Q3 2025 (shares rose 16% over the following quarter), a 69% trim in Q1 2026 (shares fell 9% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 111.70K | $25.23M | New |
| Q4 2023 | 121.83K | $26.79M | Add |
| Q1 2024 | 144.93K | $33.29M | Add |
| Q2 2024 | 140.82K | $44.86M | Reduce |
| Q3 2024 | 113.33K | $40.61M | Reduce |
| Q4 2024 | 95.42K | $33.67M | Reduce |
| Q1 2025 | 78.05K | $24.06M | Reduce |
| Q2 2025 | 67.53K | $19.40M | Reduce |
| Q3 2025 | 43.43K | $18.21M | Reduce |
| Q4 2025 | 37.02K | $18.04M | Reduce |
| Q1 2026 | 11.46K | $6.80M | Reduce |
| Q2 2026 | 10.66K | $5.78M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About UTHR and 13F data
UTHR (UNITED THERAPEUTICS CORP DEL) is a Health Care company. 43 other funds we track also report a position in UTHR — the largest reported positions include Avoro Capital Advisors LLC (US$1.51B), Renaissance Technologies (US$925.8M), ASSETMARK, INC (US$338.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding UTHR
- Avoro Capital Advisors LLC 2.78M sh · $1.51B · Q2 2026
- Renaissance Technologies 1.71M sh · $925.85M · Q2 2026
- ASSETMARK, INC 624.07K sh · $338.14M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 457.00K sh · $247.62M · Q2 2026
- Vestal Point Capital, LP 435.00K sh · $235.70M · Q2 2026
- Eversept Partners, LP 287.67K sh · $155.87M · Q2 2026
More on Nitorum Capital, L.P.
FAQ
How long has Nitorum Capital, L.P. held UTHR?
Nitorum Capital, L.P. has disclosed UTHR holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Nitorum Capital, L.P.'s current position in UTHR?
As of Q2 2026, Nitorum Capital, L.P. holds 10.66K shares of UTHR (UNITED THERAPEUTICS CORP DEL), valued at $5.78M, representing 3.94% of its reported portfolio and ranking #12.
Has Nitorum Capital, L.P. been buying or selling UTHR?
In the latest 13F filing (Q2 2026), Nitorum Capital, L.P. reduced its position in UTHR. The position peaked in Q2 2024 at 140.82K shares.
Which other funds hold UTHR?
Other major institutional holders of UTHR include Avoro Capital Advisors LLC, Renaissance Technologies, ASSETMARK, INC, among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.